BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 21982682)

  • 1. Immunostimulatory CpG-DNA and PSA-peptide vaccination elicits profound cytotoxic T cell responses.
    Maurer T; Pournaras C; Aguilar-Pimentel JA; Thalgott M; Horn T; Heck M; Heit A; Kuebler H; Gschwend JE; Nawroth R
    Urol Oncol; 2013 Oct; 31(7):1395-401. PubMed ID: 21982682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide.
    Miconnet I; Koenig S; Speiser D; Krieg A; Guillaume P; Cerottini JC; Romero P
    J Immunol; 2002 Feb; 168(3):1212-8. PubMed ID: 11801657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
    Lubaroff DM; Karan D
    Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction Sensitive PEG Hydrogels for Codelivery of Antigen and Adjuvant To Induce Potent CTLs.
    Kapadia CH; Tian S; Perry JL; Luft JC; DeSimone JM
    Mol Pharm; 2016 Oct; 13(10):3381-3394. PubMed ID: 27551741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
    Davila E; Celis E
    J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.
    Roos AK; Pavlenko M; Charo J; Egevad L; Pisa P
    Prostate; 2005 Feb; 62(3):217-23. PubMed ID: 15389792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells.
    Warren TL; Bhatia SK; Acosta AM; Dahle CE; Ratliff TL; Krieg AM; Weiner GJ
    J Immunol; 2000 Dec; 165(11):6244-51. PubMed ID: 11086059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
    Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
    Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA.
    Pavlenko M; Leder C; Roos AK; Levitsky V; Pisa P
    Prostate; 2005 Jun; 64(1):50-9. PubMed ID: 15651071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells.
    Sparwasser T; Koch ES; Vabulas RM; Heeg K; Lipford GB; Ellwart JW; Wagner H
    Eur J Immunol; 1998 Jun; 28(6):2045-54. PubMed ID: 9645386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA.
    Jakob T; Walker PS; Krieg AM; Udey MC; Vogel JC
    J Immunol; 1998 Sep; 161(6):3042-9. PubMed ID: 9743369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer.
    Lubaroff DM; Karan D; Andrews MP; Acosta A; Abouassaly C; Sharma M; Krieg AM
    Vaccine; 2006 Aug; 24(35-36):6155-62. PubMed ID: 16876291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
    Cornet S; Menez-Jamet J; Lemonnier F; Kosmatopoulos K; Miconnet I
    Vaccine; 2006 Mar; 24(11):1880-8. PubMed ID: 16300869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.
    Jérôme V; Graser A; Müller R; Kontermann RE; Konur A
    J Immunother; 2006; 29(3):294-305. PubMed ID: 16699372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
    Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.